Hung-Yu Chang1,2, Hsin-Ti Huang3, Chi-Yen Wang4, Hsu-Chung Lo4, Hsiao-Jen Chen4, An-Ning Feng1,2, Man-Cai Fong1,2, Chi-Nan Chen5, Hung-Chuan Chang5, Kuo-Feng Chiang6, Jin-Long Huang2,4,7,8. 1. Heart Center, Cheng Hsin General Hospital. 2. Faculty of Medicine, Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei. 3. Department of Internal Medicine. 4. Cardiovascular Center, Taichung Veterans General Hospital, Taichung. 5. Department of Pharmacy, Cheng Hsin General Hospital, Taipei. 6. Cardiology Division, Asian University Hospital. 7. Department of Medical Education. 8. Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Abstract
Background: The potential synergistic effect of ivabradine and cardiac resynchronization therapy (CRT) in heart failure (HF) patients has rarely been studied. We aimed to evaluate the clinical benefits of ivabradine in patients with left ventricular dysfunction following CRT implantation. Methods: Two hundred and thirty-one patients receiving CRT were consecutively enrolled between January 2014 and December 2018 from two HF centers. A total of 123 patients had left ventricular ejection fraction (LVEF) < 40% and resting sinus heart rate (HR) ≥ 75 bpm after six months of CRT implantation. Among these patients, 45 were treated with ivabradine (Group 1), and 78 did not receive ivabradine treatment (Group 2). Results: Baseline characteristics and prescription rates of HF medications other than ivabradine were similar between the two groups. In Group 1, the mean HR decreased from 82.2 ± 11.4 bpm to 76.3 ± 10.5 bpm (p = 0.012), and the mean LVEF increased from 29.9 ± 6.5% to 38.8 ± 12.4% (p < 0.001). Atrial pacing percentage, biventricular pacing percentage, and burden of atrial fibrillation (AF) were not significantly different between the two groups during the study period. The patients' daily physical activity increased significantly in Group 1 compared to Group 2 (Δ daily activity 0.4 ± 0.7 hours/day vs. -0.1 ± 7.2 hours/day, p < 0.001). Conclusions: Ivabradine could effectively reduce HR and improve physical activity. It was safe to use and did not increase AF burden or affect biventricular pacing percentage in CRT recipients.
Background: The potential synergistic effect of ivabradine and cardiac resynchronization therapy (CRT) in heart failure (HF) patients has rarely been studied. We aimed to evaluate the clinical benefits of ivabradine in patients with left ventricular dysfunction following CRT implantation. Methods: Two hundred and thirty-one patients receiving CRT were consecutively enrolled between January 2014 and December 2018 from two HF centers. A total of 123 patients had left ventricular ejection fraction (LVEF) < 40% and resting sinus heart rate (HR) ≥ 75 bpm after six months of CRT implantation. Among these patients, 45 were treated with ivabradine (Group 1), and 78 did not receive ivabradine treatment (Group 2). Results: Baseline characteristics and prescription rates of HF medications other than ivabradine were similar between the two groups. In Group 1, the mean HR decreased from 82.2 ± 11.4 bpm to 76.3 ± 10.5 bpm (p = 0.012), and the mean LVEF increased from 29.9 ± 6.5% to 38.8 ± 12.4% (p < 0.001). Atrial pacing percentage, biventricular pacing percentage, and burden of atrial fibrillation (AF) were not significantly different between the two groups during the study period. The patients' daily physical activity increased significantly in Group 1 compared to Group 2 (Δ daily activity 0.4 ± 0.7 hours/day vs. -0.1 ± 7.2 hours/day, p < 0.001). Conclusions: Ivabradine could effectively reduce HR and improve physical activity. It was safe to use and did not increase AF burden or affect biventricular pacing percentage in CRT recipients.
Authors: Anthony S L Tang; George A Wells; Mario Talajic; Malcolm O Arnold; Robert Sheldon; Stuart Connolly; Stefan H Hohnloser; Graham Nichol; David H Birnie; John L Sapp; Raymond Yee; Jeffrey S Healey; Jean L Rouleau Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Martin G St John Sutton; Ted Plappert; Kathryn E Hilpisch; William T Abraham; David L Hayes; Edward Chinchoy Journal: Circulation Date: 2006-01-09 Impact factor: 29.690
Authors: G Riccioni; L Masciocco; A Benvenuto; P Saracino; D De Viti; F Massari; G Meliota; F Buta; G Speziale Journal: Pharmacology Date: 2013-11-27 Impact factor: 2.547
Authors: Stefano F Rimoldi; Franz H Messerli; David Cerny; Steffen Gloekler; Tobias Traupe; Stéphane Laurent; Christian Seiler Journal: Hypertension Date: 2016-04-18 Impact factor: 10.190
Authors: Martin St John Sutton; Stefano Ghio; Ted Plappert; Luigi Tavazzi; Laura Scelsi; Claude Daubert; William T Abraham; Michael R Gold; Christian Hassager; John M Herre; Cecilia Linde Journal: Circulation Date: 2009-10-26 Impact factor: 29.690
Authors: Ruairidh I R Martin; Oksana Pogoryelova; Mauro Santibáñez Koref; John P Bourke; M Dawn Teare; Bernard D Keavney Journal: Heart Date: 2014-06-20 Impact factor: 5.994